LVID (mm) in C57Bl/6 mice receiving prophylactic treatment with Aliskiren, Perindopril, Valsartan or placebo prior to receiving one of the following anti-cancer drugs: A) TRZ; B) DOX; or C) DOX+TRZ. Values were represented as mean ± SD. (*) indicates p < 0.05 as compared to baseline within each group. At baseline, all the groups had n = 20. At the end of 13 weeks, TRZ alone (n = 20); Aliskiren+TRZ (n = 20); Perindopril+TRZ (n = 20); Valsartan+TRZ (n = 20); DOX alone (n = 10); Aliskiren+DOX (n = 16); Perindopril+DOX (n = 14); Valsartan+DOX (n = 14); DOX+TRZ (n = 6); Aliskiren+ DOX+TRZ (n = 14); Perindopril+DOX+TRZ (n = 11); and Valsartan+DOX+TRZ (n = 10).